Dr.Umesh Bhammarkar, B12247
To study the clinical safety and efficacy of Razumab for the treatment of macular pathology.
Retrospective analysis of 51 eyes with macular pathology treated with Razumab with at least 12 months follow-up time. Macular edema was diagnosed by clinical examination, Fundus photo and OCT.
Patients’ data were collected and included details BCVA by Snellen chart and OCT at baseline and on each visit during follow-up. Number of injections and potential complications were recorded. Outcome measures were safety parameters that included signs of clinical ocular toxicity and changes in best-corrected visual acuity (BCVA) and central macular thickness (CMT) on OCT, respectively.
The biosimilar ranibizumab for DME, nAMD, and macular edema secondary to RVO was well tolerated with improvements in BCVA and CFT without any detectable ocular and systemic toxicity.
This short-term results suggest that biosimilar ranibizumab could become a safe, low-cost therapy for macular edema.
Leave a Comment